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ABSTRACT OF DISSERTATION

LAYERED, FLEXIBLE DRUG DELIVERY FILMS FOR THE
PREVENTION OF FIBROTIC SCAR TISSUE FORMATION

Open wounds account for about 50% of military injuries and 10% of non‐fatal
traffic injuries. Scar tissue formation in these wounds may be reduced or prevented if
treated with a combination of molecules whose release is tuned to the healing phases.
The goal of this research was to develop flexible, layered drug delivery films for
sequential, localized release of anti‐inflammatory, anti‐oxidant, and anti‐fibrotic
molecules to soft tissue.
Films were composed of cellulose acetate phthalate (CAP) and Pluronic F‐127
(Pluronic). To impart flexibility, plasticizers, triethyl citrate (TEC) or tributyl citrate (TBC),
were added. Mechanical analysis was performed on films as prepared and following
phosphate‐buffered saline incubation to determine property changes after
implantation. Tensile tests revealed higher plasticizer content increased film elongation
but decreased elastic modulus and ultimate tensile strength. TEC films elongated twice
as much as those with TBC. After incubation, properties increased because plasticizer
leached from films. Micro computerized tomography and scanning electron microscopy
determined how erosion and plasticizer leaching affected the film’s structures before
and after incubation. Porosity increased as plasticizer content increased; however,
plasticizer content did not significantly affect erosion rates.
Next, effects of drugs with plasticizers on film erosion, release, and mechanical
properties were investigated. Films were loaded with quercetin, an anti‐oxidant, or
pirfenidone, an anti‐fibrotic, and plasticized with TEC or TBC. TEC‐plasticized films
containing quercetin released drug at a slower rate than TBC films. Pirfenidone‐loaded
films released drug at a faster rate than erosion occurred for both plasticizers.
Increased pirfenidone loading resulted in significantly higher modulus and decreased
elongation, an anti‐plasticizer effect. Increasing quercetin loading significantly increased
elongation.
Size, solubility, and structure differences between quercetin and
pirfenidone affected drug interaction with the films and the consequent mechanical and
release properties.
Cell studies found TBC to be toxic even in low concentrations. Consequently,
only TEC was further analyzed. Layered devices containing two drugs demonstrated

sequential release regardless of drug order. Plasticizer concentration did not
significantly affect the release profiles. Lastly, in vitro and in vivo 9‐layered device
studies sequentially released drugs confirming the research objective: sequential, local
release of anti‐inflammatory, anti‐oxidant, and anti‐fibrotic molecules from CAP‐
Pluronic films.

KEYWORDS: Drug delivery, mechanical properties, plasticizer, cellulose acetate
phthalate, Pluronic F‐127.
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Chapter 1
Introduction

Open wounds accounted for 10.3% of the 5.3 million non‐fatal injuries from
traffic collisions in the U.S. in 2000, and about 50% of all military injuries involve
musculoskeletal wounds to the extremities (1, 2). Chronic inflammation in these types
of soft tissue defects can result in scars that have functional and aesthetic
consequences. Fibrotic scar formation in these wounds may be reduced or prevented if
treated with a combination of anti‐inflammatory, anti‐oxidant, and anti‐fibrotic
molecules targeted to the different healing phases. As such, the objective of this
research was to develop and characterize flexible, layered drug delivery films for
sequential, localized release of the aforementioned molecules to soft tissue.
Chapter 2, provides a review of the current state of the art on treatments for
large soft tissue defects and a critical analysis of their shortcomings and potential areas
of development. Scarless healing is examined and ongoing research in wound healing
and drug delivery devices are discussed. To work towards developing a soft tissue
wound healing device, mechanical and erosion properties of the system were evaluated
(Chapter 3), drug release mechanisms were determined (Chapter 4), the cellular impact
and capability of sequential release were assessed (Chapter 5), and finally in vivo studies
were performed (Chapter 6). The films examined in this research are composed of two
polymers, cellulose acetate phthalate (CAP) and Pluronic F‐127 (Pluronic). Alone the
1

films are rigid. Since every wound has its own geometry and topography, the films need
to be flexible and able to contour to the shape of any wound. To impart flexibility,
plasticizers, triethyl citrate (TEC) or tributyl citrate (TBC), were added. In the third
chapter, mechanical analysis was performed on plasticized films as prepared and
following phosphate‐buffered saline incubation to determine property changes after
implantation.

Micro computerized tomography and scanning electron microscopy

determined how erosion and plasticizer leaching affected the film’s structures before
and after incubation.
The combined effects of drugs with plasticizers on film erosion, release, and
mechanical properties were investigated in Chapter 4.

Films were loaded with

quercetin, an anti‐oxidant, or pirfenidone, an anti‐fibrotic, and plasticized with TEC or
TBC. Size, solubility, and structure differences between quercetin and pirfenidone were
determined to affect how the drugs interacted with the films and the consequent
mechanical and release properties.
In Chapter 5, cell studies were performed to evaluate the cytotoxicity of the TEC
and TBC. The effect the plasticizers had on the mechanical properties of the films and
the cytotoxicity results narrowed down the plasticizer choice for multi‐layered devices.
Two different multi‐layered device types were evaluated, 4‐layered devices and 9‐
layered devices.

Both types demonstrated sequential drug release.

Again, the

differences in the drugs were found to affect the resulting release profiles. Pilot animal
trials were performed to evaluate the devices in vivo and compare against in vitro
2

results in Chapter 6.

Lastly, Chapter 7 is an assessment and conclusion of the

developed and characterized devices against the objectives.

Copyright © Cheryl Lynn Rabek 2015
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Chapter 2
Background and Significance

2.1 Clinical Need
With soft tissue defects accounting for over 10% wounds inflicted from motor
vehicle accidents, over half a million car accident victims every year could benefit from
wound healing films (1). Additionally, wounds caused during war, industrial accidents,
or surgeries could also heal faster and with less scarring by the proposed drug delivery
films.

2.2 Wound Healing
There are two categories of wound repair: primary unions and secondary unions
(3). An example of a primary union wound is a surgical incision. The wound is narrow
and clean and a limited number of epithelial and tissue cells die. Secondary unions are
wounds in which a large mass of tissue has been destroyed and the wound cannot be
neatly sewn together with sutures (4, 5). The healing steps are the same for secondary
union and primary union wounds, but with secondary union wounds the process is
longer, more complex, and the wound experiences more inflammation ultimately
resulting in excessive scar tissue formation (6). Specifically, secondary union wound
healing is the target of this research.
4

Wound healing is a complex process involving four main phases: hemostasis,
inflammation, proliferation, and remodeling (7, 8). After the initial injury to tissues, the
body undergoes hemostasis to stop blood loss (7, 9). During this phase, blood vessel
walls have been damaged and platelets adhere to the collagen fibers present at the
ruptured vessel walls.

The platelets degranulate releasing adenosine diphosphate

(ADP), calcium, and serotonin (10). These biomolecules or tissue damage initiates the
plasma coagulation cascade. Incoming platelets exposed to ADP begin aggregating and
start forming a platelet plug (11). The platelets degranulate further causing additional
aggregation of platelets. Fibrinogen present in blood plasma is converted to fibrin
which strengthens the clot.
Once blood loss is successfully controlled, the wound site undergoes
inflammation (12). The signs of inflammation are redness, swelling, heat, pain, and
sometimes loss of function. Preexisting chemical mediators, including histamine and
serotonin, are released from local platelets and mast cells (3, 13, 14). These chemical
mediators cause the surrounding vasculature to become leaky, predominately by
endothelial cell retraction which causes a widening of the intercellular junctions (15,
16). The leaky vasculature allows an influx of fluid and cells into the injured tissue.
Increased blood flow and fluid cause the previously mentioned signs of inflammation.
Chemokines, chemotactic cytokines, are released by proximate cells and which causes
recruitment of more cells to the area (17). The majority of the cells to enter the injured
tissue are neutrophils and monocytes (10). They synthesize and release additional
5

chemical mediators, including arachidonic acid metabolites: prostaglandins and
leukotrienes, cytokines, and nitric oxide (3). Nitric oxide and prostaglandins cause
vasodilation allowing for the influx of more cells and extracellular fluid (18). The
cytokines and leukotrienes activate other leukocytes to perform their inflammatory
roles. Neutrophils protect against invading pathogens. Monocytes can differentiate
into macrophages, which break down dead or invading cells and impurities through
phagocytosis. Macrophages can congregate into one larger foreign body giant cell
(FBGC) and remove larger debris (10). In normal healing, inflammation is a self‐limiting
process and the release of inflammatory mediators will reduce and cells will retract as
the threat is resolved (19, 20). In chronic healing, the chemical mediators exacerbate
the inflammation.
The next phase, the proliferation phase, replaces lost or damaged tissue.
Angiogenesis occurs from surrounding blood vessels (21, 22). Macrophages present in
the wound secrete epidermal growth factor (EGF) and vascular endothelial growth
factor (VEGF). These cause endothelial cells in the blood vessels to bud and branch
towards the wound, allowing for the exchange of nutrients and waste. Within a couple
days, fibroblasts migrate to the injured tissue (23). The fibroblasts proliferate and
create the proteoglycans and proteoglycan aggregates in the extracellular matrix (24).
They repair the damaged tissue by forming a collagen matrix. If inflammation is not
reduced, chemotaxis recruits excess fibroblasts to the newly formed granulation tissue.
Growth factors, including platelet‐derived growth factor (PDGF), fibroblast growth
6

factor (FGF), and transforming growth factor (TGF), cause fibroblasts to differentiate
into proto‐myofibroblasts (25‐27). Then the proto‐myofibroblasts differentiate into
myofibroblasts which are responsible for expression of smooth muscle actin and create
the contractile forces in the tissue (28).
Remodeling is the maturation of the scar tissue (3, 7, 12). This is the longest
phase of all four since it can last for months.

If inflammation continues during

remodeling, cytokines and growth factors stimulate secretion of collagenases that
breakdown the newly formed scar tissue (29). The collagen fibers will continue to be
realigned, which can cause the contractile forces to become greater over time (30‐32).
These forces can cause disfiguration and malfunction around the injury site leading to
the development of contracture, hypertrophic, or keloid scars (33‐35).

2.3 Current Treatments
Secondary union wounds often contain bacteria (36). Either the object that
severed the skin was unclean or the wound becomes susceptible to bacteria because of
the large amount of exposed soft tissue (37). These wounds may also contain foreign
materials. The first step to treating secondary union wounds is debridement, the
process of removing foreign debris and dead tissue (6). There are five main types of
debridement: surgical, mechanical, enzymatic, biosurgery, and autolytic (38, 39). In
surgical debridement, necrotic tissue is surgically cut away and debris is removed with
sterile tools. Saline irrigation, vacuum‐assisted closure, ultra sound, and wound
7

redressing are types of mechanical debridement (39, 40).

Pharmaceutically

manufactured proteolytic enzymes are used applied to wounds in enzyme debridement.
Collegenase is one of the most common enzymatic debridement methods because it
selectively breakdowns triple helical collagen and disregards other proteins (29). In
biosurgery debridement, sterilely grown maggots are applied to the wound to remove
necrotic tissue (39, 40).
responses.

Autolytic debridement naturally occurs through cellular

Macrophages and FBGCs phagocytose debris and necrotic tissue (41).

Phagocytosis occurs on the micron scale so some material can be too large or resistant
for macrophages and FBGCs to break down (41, 42). If the debris is not removed a
fibrous capsule will form around it (10). If a wound is infected, bacteria can create
necrotic tissue faster than the macrophages and FBGCs can eliminate it. Depending on
the severity of the wound, intravenous or oral antibiotics may also given
prophylactically to kill any present bacteria (43).
Once the wound is cleaned, bandages are applied.

Bandages are typically

redressed every couple days (37). If a wound is too large for epithelium to fill in the
defect, a skin graft may be required for the wound to close (6). There are a two
different categories of skin grafts: split‐thickness skin grafts (STSG) and full‐thickness
skin grafts (FTSG) (44). Several factors must be considered before selecting a donor site,
including contour, color, and vascularity. If a wound has not responded to traditional
wound treatment, negative pressure wound therapy (NPWT) or vacuum‐assisted closure

8

can also be used (45). NPWT creates a physical barrier, removes excess fluid, allows the
wound to stay moist, and increases perfusion and granulation tissue formation (39).
Even though the treatment is more or less the same for all secondary union
wounds, the healing time is not. Healing rates of chronic wounds are negatively
affected by increased age of the individual wounded, increased size and decreased
perfusion of the wound, and by reduced nutrition and health of the patient (3, 6, 46).
Ischemia, diabetes, edema, and infection can also cause adverse healing (8).

If

inflammation continued through the remodeling phase, keloid, contracture, or
hypertrophic scars are likely to develop (35). Once formed, treatments of these scars
include surgical removal, cryotherapy, laser resurfacing, and steroid injections (47‐50).
If these treatments are utilized, the healing process of that location will occur again.
Secondary union wounds often cause fibrotic scar tissue with aesthetic and functional
consequences.

There is much room and need for improvement upon current

treatments.

2.4 Current Research
2.4.1 Scarless Wound Healing
During early development, human fetuses heal without any evidence of a scar
(51‐54). Fetal skin experiences a very minimal inflammation process during wound
healing, which is related to the levels of cytokines and growth factors present (52).
Transforming growth factors β1 and β2 have been shown to play a large role in the
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development of a fibrotic scar experimentally. In fetal wounds, these are exhibited at
very low levels (52). Interleukins (IL) 6 and 8 are found in low levels in fetal wounds and
are much higher in adult wounds, while IL‐10, a known anti‐inflammatory biomolecule,
is found in higher concentrations in fetuses than in adults.

As discussed earlier,

myofibroblasts mediate fibrotic tissue formation in adults; myofibroblasts are not even
present in fetal flesh wounds until late gestation (52, 55). Knowledge gained through
experiments with fetal wound healing can give insight into effective strategies to
combat scar tissue formation in adult wounds.

2.4.2. Growth Factors and Wound Healing
As described above, the levels of growth factors present in a wound play a direct
role in wound closure and scar formation. Hence, research is being conducted to better
understand the effects of growth factors, including TGF, PDGF, FGF, and EGF, on wound
healing (27, 56, 57). The effect of (EGF) on cutaneous scar formation in mice revealed
that daily treatment, 100 µg, resulted in a third faster healing rate as compared to the
saline treated control (58). The average scar size of the control group was 1.44 times as
large as the average scar of the EGF treated group and the number of inflammatory cells
present in the histological samples and the expression of TGF‐β1 were much less for the
EGF treated group (58).

The concentration of EGF was found to be inversely

proportional to the degree of scarring.
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To study the effect of fibroblast growth factor (FGF) on wound healing, full‐
thickness dermal wounds were created in a rodent model (59). Chitosan films loaded
with FGF were placed on the cutaneous wounds.

There were three groups of

experimental mice. One group’s films were loaded with 0.6 μg of FGF, another with 2.0
μg of FGF, and another with 6.0 μg of FGF. Another group of mice received an unloaded
chitosan films on their wounds and the control group received only saline on their
wounds. The FGF loaded chitosan films reduced the wound size and sped up the healing
rate in a dose‐dependent way (59). Histology revealed that the control group didn’t
receive as high of an influx of macrophages and fibroblasts that the other groups did,
nor did they experience as high a degree of angiogenesis in the healing wounds. In
addition, FGF treated mice had more granulation tissue at the wound site as compared
to the control.
Ischemic wounds often have adverse healing with excess inflammation (60, 61).
PDGF and VEGF are growth factors that promote angiogenesis and correct an ischemic
wound. Ischemia was inflicted on the hind limbs of mice (62). Immediately following
surgery and again 5 days later, the experimental mice were treated with either PDGF,
VEGF, or both PDGF and VEGF. Twenty one days after ischemia, the limbs treated with
PDGF or both PDGF and VEGF had over 1.5 times the blood flow than the VEGF treated
group or the control implying that PDGF is more important to ischemic wounds that
VEGF (62).
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2.4.3 Wound Healing Devices
Many different materials are being explored for drug delivery devices for wound
healing applications including alginate (63‐65), carboxymethylcellulose (66, 67), chitosan
(68‐71), collagen (72), dextran (73), hydrogels (65, 74‐78), hydroxypropylmethylcellulose
(HPMC) (79, 80), poly(vinyl alcohol) (PVA) (70, 81, 82), polycaprolactone (PCL) (83‐85),
poly(lactic‐co‐glycolic acid) (86‐88), polyurethane (80, 89), and silk (86, 90, 91).
Although all of these materials have been well studied for a variety of applications, very
few are being evaluated as implantable wound healing devices.

Instead, their

effectiveness as topical dressings has been explored.
Porous gelatin and hyaluronic acid scaffolds were investigated as wound healing
devices (92). When placed over split thickness wounds in a rat model, wound closure
was accelerated and collagen deposition increased compared to the control which was
no treatment. Electrospun wound dressings composed of PLGA and silk fibroin were
shown to have a significant effect on wound closure in rats compared to PLGA dressings
alone and the positive and negative controls after 15 days (86). Although the gelatin
and hyaluronic scaffolds and PLGA fibroin wound dressings demonstrated an
improvement to the control, they were replaced on the wounds every 24 and 48 hours,
respectively, which is not possible with an implantable system.
Another challenge for implantable systems is coordinating the rates of drug
release and erosion of the device. In topical wound dressings, that does not have to be
considered.

Films composed of electrospun PVA and PCL fibers and loaded with
12

caffeine, used as a model drug, were analyzed as potential flexible wound healing
devices (93). These PVA and PCL films release drug on the order of hours and degrade
on the order of weeks limiting the films to only dermal applications (84, 94). If these
devices were implanted, they would leave behind material to cause an inflammatory
response for far longer than the duration of the treatment (93). Hydrogels crosslinked
with glutaraldehyde and loaded with gentamicin sulfate or norfloxacin were explored as
an antimicrobial wound dressing (74). A full thickness dorsal wound was created in rats
and the hydrogel was applied. Histology performed after 21 days revealed that the
glutaraldehyde cross‐linked hydrogels were found to have broken down into fragments
and elicited an inflammatory response that interfered with the wound healing process
(74) highlighting another challenge of the development of wound healing devices.

2.5 Proposed System
2.5.1 CAP‐Pluronic
For over 20 years cellulose acetate phthalate combined with Pluronic F127 has
been known to be a surface eroding drug delivery system (95). CAP and Pluronic can be
easily fabricated into films, cylinders, or microspheres that can release a variety of
different drugs (95‐100). When loaded with drug in layers, devices were shown to
release the drugs in a pulsatile manner (97, 100). Erosion and release rates of the
system can be adjusted by changing the ratio of CAP:Pluronic; increasing Pluronic
content increases the erosion and release rates while increasing CAP content decreases
13

the rates (95). The release mechanism from CAP‐Pluronic devices is pH dependent. In
neutral and basic conditions release is controlled through surface erosion and in acidic
conditions, release is diffusion controlled (95). Previous studies have proven the system
to be capable of releasing multiple drugs over several days, which is why it was chosen
for this evaluation as a wound healing device.

2.5.2 Plasticizers
The CAP‐Pluronic system alone is rigid. To allow a CAP‐Pluronic film to contour
to the varying geometries of a wound, plasticizers need to be added (101). There are
several different families of plasticizers that are commonly used in medical and
pharmaceutical applications (102‐104). Glycols, citrates, sebacates in particular are
frequently used to plasticize cellulose acetate (104). Phthalates were also commonly
used to plasticize CAP, but in recent years, long term phthalate exposure has proven to
have an adverse impact on health and development (105, 106). Triethyl citrate and
tributyl citrate were chosen for the wound healing device developed because of their
lower effect on erosion rates as compared to other plasticizers in addition to their
biocompatibility.

2.5.3 Anti‐inflammatory Drugs
There are two classes of anti‐inflammatory drugs: steroidal and non‐steroidal.
Steroidal anti‐inflammatory drugs typically require prescriptions and side effects can be
14

severe (107).

Non‐steroidal anti‐inflammatory drugs (NSAIDs) act by inhibiting

formation of prostaglandins by inhibiting the cyclooxygenase (COX) pathways that
create them (108). There are two types of cylcooxygenase enzymes, COX‐1 and COX‐2.
COX‐1 is a common enzyme in healthy tissue and the inhibition of it can lead to
gastrointestinal damage (109). Unselective NSAIDs inhibit prostaglandin synthesis by
blocking both COX enzymes where selective NSAIDS preferentially inhibit either COX‐1
or COX‐2 enzymes (110). There are many different NSAIDs on the market including
ibuprofen, acetaminophen, and aspirin. The drug delivery devices were evaluated in
rodents first. NSAIDs approved for use in rodents include ketoprofen and meloxicam, so
they were chosen for the device (108).

2.5.4 Anti‐oxidant Drugs
There are two types of anti‐oxidants: enzymatic and non‐enzymatic. Of the non‐
enzymatic anti‐oxidants, many different families exist: carotenoids, minerals, phenols,
thiols, and vitamins (111, 112). They all reduce oxidative stress through a variety of
mechanisms (113). Quercetin, a highly abundant dietary phenol, was chosen as the
anti‐oxidant drug for the device. Quercetin decreases superoxide activity of leukocytes
and acts as a pro‐inflammatory mediator (114‐116).
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2.5.5 Anti‐fibrotic Drugs
Pirfenidone was the anti‐fibrotic drug chosen for the wound healing film.
Through several double blind studies, pirfenidone has proven to be an effective
treatment for fibrotic diseases (117, 118). Pirfenidone reduces scar tissue formation by
down‐regulating cytokines and growth factors, including interleukin 1β and
transforming growth factor‐β1 (119‐123). Other drugs, including imatinib mesylate and
rosiglitazone, were developed as therapies for different conditions but inhibit pathways
that create fibrosis. Imatinib mesylate inhibits growth factor receptors on mast and
stem cells and rosiglitazone reduces inflammation that leads to fibrosis by reducing the
inflammatory signally molecule, nuclear factor kappa‐B (124‐130).

2.6 Significance
Little research is currently being conducted on wound healing systems with the
distinct aim of reducing fibrotic scar tissue formation. For an implantable drug delivery
device to be effective at preventing scar tissue, it needs to be capable of altering the
mechanisms of fibrotic tissue formation by providing therapeutic molecules over an
extended period of time. The device also needs to erode as it delivers drug or be
biologically inert, so the remaining vehicle does not perpetuate an inflammatory
response (131, 132). Although research on topical wound dressings or treatments are
promising, they require application of the therapeutic molecules on a daily basis over
several weeks and cannot be implanted, only treat on one healing front by releasing
16

only one molecule, or leave behind a polymer vehicle in the wound that could cause
adverse healing. There is a need for devices that are applied or implanted once, are
capable of sequential release of multiple molecules to heal on multiple fronts, and
erode as drug is released.

This research was focused on the development and

characterization of CAP‐Pluronic films loaded with anti‐inflammatory, anti‐oxidant, and
anti‐fibrotic drugs for local delivery to soft tissue defects, with the ultimate goal of
preventing or reducing fibrotic scar tissue formation and encouraging proper wound
healing.

Copyright © Cheryl Lynn Rabek 2015
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Chapter 3
The Effect of Plasticizers on the Erosion and Mechanical Properties of Polymer Films

This chapter reproduced from a published manuscript, “Rabek C. L., Van Stelle
R., Dziubla T.D., and Puleo D.A. , The Effect of Plasticizers on the Erosion and Mechanical
Properties of Polymer Films. Journal of Biomaterials Applications. 2014; 28(5): p. 779‐
89.”

3.1 Introduction
While convenient, medications taken orally must make a long journey, traveling
from the intestines, through the portal vein, into the liver, through the bloodstream
until finally reaching their intended therapeutic target. During this convoluted process,
many drug molecules are eliminated from circulation by the liver and kidneys,
metabolized and excreted from the body (133‐136). Because of this, oftentimes drugs
must be given at doses far exceeding what the target site needs for treatment. This
excessive concentration coupled with presence of the drug throughout all of the body
systems results in a scenario where systemic side effects are guaranteed (137‐139).
As a result, there is a need for a degradable, localized, drug delivery system
capable of delivering drug to soft tissue so unnecessary sites are not medicated,
reducing the risk of side effects, and drug is not wasted during clearance. Most of the
current drug delivery systems are composed of slowly eroding polymer networks,
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including Eudragit and poly(sebacic anhydride), from which drug diffuses out to provide
therapy (140‐145). This kind of device leaves behind material that may cause a foreign
body reaction or cause inflammation from the byproducts as it slowly degrades. Also,
many of the other currently researched systems are composed of rigid polymers, such
as chitosan and Eudragit, that cannot contour to the shape of the treated site (145‐147).
The rigidity or stiffness of materials is related to their elastic modulus (148). Rigid
polymers implanted in soft tissue will cause discomfort and possible fibrous capsule
formation (10, 149, 150).
Plasticizers can be added to polymers to make them more flexible (102, 104).
Plasticizers are small lubricating molecules that can change polymer properties and
processability (104). In this study, the effect of plasticizers on the mechanical properties
of an association polymer was explored. The system formed from cellulose acetate
phthalate (CAP) and Pluronic F‐127 has been proven to be a surface‐eroding system that
would release drug as the device eroded so no material would be left behind to cause
an inflammatory reaction (95, 96, 151). Without plasticizer, however, the polymer is
rigid and cannot be readily contoured. Two plasticizers, triethyl citrate (TEC) and
tributyl citrate (TBC), have been included, and the system as a whole has been
evaluated through mechanical analysis and degradation studies.

Because these

materials are ultimately intended to be implanted, their properties and structure when
wet were also determined (152, 153).
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3.2. Materials and Methods
3.2.1 Film Production
Films were made with a 70:30 weight percent ratio of cellulose acetate phthalate
(CAP; Sigma‐Aldrich, St. Louis, MO) and Pluronic F‐127 (Sigma‐Aldrich), respectively
(Figure 3.1). Plasticizer, either tributyl citrate (Sigma‐Aldrich) or triethyl citrate (Sigma‐
Aldrich), was added to the CAP‐Pluronic mixture at either 0, 10, or 20 wt%. Acetone was
added to make a 25% (w/v) solution.

After vortexing the solution to ensure

homogeneity, it was cast into Teflon dishes and then let stand in a 10ºC refrigerator
overnight. Films were desiccated overnight before testing.
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Figure 3.1: Chemical structures of Pluronic F127 (a), cellulose acetate phthalate
(b), triethyl citrate (c), and tributyl citrate (d).
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3.2.2 Erosion Studies
Films were cut into discs using a circular punch measuring 5 mm in diameter.
After determining their initial mass, samples were placed individually in a 24‐well plate,
and 1.85 ml of phosphate‐buffered saline (PBS), pH 7.4, was added to each well. Plates
were incubated on an orbital shaker plate 37ºC. Half of the supernatant was replaced
with fresh PBS every 12 hours. Three samples were collected and dried at different time
points ranging from every 3 to 5 hours. Dried samples were weighed to determine final
mass. The average mass loss was determined. The erosion rates were found by
calculating the slope of average mass loss with time. Supernatants were collected from
both TEC and TBC films after being incubated in PBS for 2 hours. The supernatants were
pipetted into a 96‐well plate and UV absorbance was measured at 630 nm using the
BioTek PowerWave HT and Gen5 software to determine the opacity. PBS was used as a
control.

3.2.3 Mechanical Properties
Films were cut to make microtensile test samples using a dog bone die (ASTM D
1708). Wet samples were incubated in 4 ml of PBS for two hours. Cross‐sectional areas
were measured for each film, both wet and dry, using calipers.

Samples were

mechanically tested to failure in tensile mode using the BOSE ELF 3300 with a ramp at a
displacement rate of 0.5 mm/sec.

Stress and strain were calculated, and elastic

modulus (E), percent elongation, and ultimate tensile strength (UTS) were determined.
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The percent elongation was normalized by the cross‐sectional area so this value would
not be influenced by thickness variations in the cast films.

3.2.4 Scanning Electron Microscopy
After dog bones were incubated in PBS for two hours, they were lyophilized and
frozen at ‐80ºF for 30 min. Samples were then fractured so the cross‐sectional area
could be analyzed using a model S‐3200‐N Hitachi scanning electron microscope. The
samples were coated with gold, and the microscope was operated at 20 kV and digital
images were collected.

3.2.5 Microcomputerized Tomography (MicroCT)
To determine the interior porosity, microCT scans were performed using the
SCANCO Medical AG µCT 40. Samples were cut to fit 12.3 mm tubes and were batch
scanned. Scans were run in high resolution having 1000 projections with 2048 samples,
a current of 177 µA, a potential of 70 kVp, and a 0º angle. Samples were contoured and
evaluated with a program that distinguished between the polymer material and
vacancies. The uniformly biased lower threshold was set to 20 so any part of the scan
with a density below that was considered a void.

The slices were reconstructed into a

3‐dimensional representation of the scanned samples, from which the total volume,
porosity volume, average pore size, and average spacing between pores were calculated
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using a morphometry script. Samples were scanned before and after being incubated in
PBS for two hours.

3.2.6 Mass Spectroscopy
Mass spectra were acquired by the University of Kentucky Mass Spectrometry
Facility. Supernatants from erosion studies were mixed an equal volume of acetonitrile
before analysis.

Electrospray ionization mass spectra were obtained on a

ThermoFinnigan LTQ (ion trap mass spectrometer), with sample introduction by direct
infusion at 3uL/min. Full scan mass spectra were recorded in positive ion mode.
Instrument parameters included spray voltage: 3.5kV, capillary temperature: 185C,
capillary voltage: 50V, and tube lens voltage: 80V

3.2.7 Statistical analysis
Statistical analysis was performed using Instat (GraphPad Software). All of the
samples with the same weight percentage of plasticizer or the same type of plasticizer
were compared against each other. Results were analyzed using two‐way ANOVA, and a
p‐value < 0.05 was considered statistically significant.
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3.3 Results
3.3.1 Films
Plasticized films increased in flexibility as plasticizer content increased, while the
unplasticized films remained rigid and could not be plastically deformed without failure
(Figure 3.2). Qualitatively, films plasticized with TEC were more flexible than those
plasticized with TBC at an equivalent weight percentage.

A

B

Figure 3.2: A) Unplasticized inflexible CAP‐Pluronic film and B) plasticized CAP‐
Pluronic film able to conform to any shape.

3.3.2 Erosion Studies
Figure 3.3 shows typical mass loss curves for the control (unplasticized) and
plasticized films. The addition of plasticizer did not significantly affect the erosion of the
films. As the weight percentage of plasticizer increased, the magnitude of rate of
erosion slightly increased from 2.2 wt% to 2.4 wt% per hour but the differences
24

between the three rates were not significant (Figure 3). As the films eroded, collecting
the residual polymer to measure mass loss became a challenge so samples were only
collected for the first 24 hours. The remaining mass of all of the films, plasticized with
either TEC or TBC, after 16 hours was also statistically the same (Figure 3.4). Sixteen
hours was chosen because at that point the initial mass loss due to plasticizer leaching
had already occurred and the supernatant had been replenished with fresh PBS
resulting in close to sink conditions. As TBC films eroded, the PBS became milky in
appearance, whereas the supernatant remained transparent as TEC films eroded (Figure
3.5). Quantitatively, the opacity of the supernatant from the TBC sample was over 10
times as high as the TEC sample. The supernatant from the TEC sample was the same as
PBS alone. Supernatants were analyzed by mass spectroscopy and after two hours the
mass‐to‐charge ratios corresponding to TEC and TBC had a higher relative abundance
than any other peak.
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Figure 3.3: Example of typical degradation curves. Data are mean ± standard deviation
(n=3).
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Figure 3.4: Remaining mass after 16 hours of incubation in PBS at 37ºC. Data are mean
± standard deviation (n=3). No differences were statistically significant.
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Figure 3.5: Absorbance at 630 nm of supernatants from TEC and TBC films after
2 hours of incubation compared to PBS. Data are mean ± standard deviation (n=3).
Inset: Images showing appearance of supernatants from TEC (above) and TBC (below)
films.

3.3.3 Mechanical Properties as Prepared
Increasing the plasticizer content increased the effects on the mechanical
properties; more plasticizer decreased the E and UTS and increased the percent
elongation. Compared to unplasticized films, the 20 wt% samples plasticized with TEC
had a lower E and UTS (Figures 3.6a and 3.6b), by about half, but had a 5 times higher
percent elongation (Figure 3.6c). Addition of TEC to the films always significantly (p ≤
0.05) affected the mechanical properties except between the ultimate tensile strength
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of the 10 wt% TEC and unplasticized samples.

Adding 10 wt% TBC to the films

decreased the UTS by roughly half, but addition of more TBC did not further affect the
UTS. The 0 wt% TBC films had an elongation that was statistically the same as the 10
wt% TBC films, which had an elongation that was comparable to that of the 20 wt% TBC
films. However, 0 and 20 wt% TBC films had elongations significantly (p ≤ 0.05) different
from each other. The elastic modulus did significantly (p ≤ 0.001) decrease as more TBC
was added to the films. For the concentrations examined, as plasticizer increased, the
UTS of the TEC films decreased. With the TBC films, increasing plasticizer concentration
past 10 wt% did not significantly affect the UTS. For similar plasticizer content, TEC
caused greater changes to elongation, UTS, and E. For the 20 wt% samples, the TEC and
TBC films had statistically similar UTS and E values, but their elongations were
statistically different (p < 0.001), with and the 20 wt% TEC films plastically deforming
over twice as much as the TBC films.
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(a)

(b)
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(c)

Figure 3.6: A) UTS of TBC and TEC films. 0 and 20 TEC were statistically different,
p < 0.001. 0 and 20 TBC were statistically different, p < 0.01. B) Elastic modulus of TBC
and TEC films. 0, 10, and 20 TBC were all statistically different from each other, p < 0.01.
Both 10 and 20 TEC were statistically different from 0 TEC, p < 0.001 but 10 and 20 TEC
were statistically the same. C) Elongation of TBC and TEC films normalized by the cross‐
sectional areas (CSA). 0 samples are statistically different from 20 TBC samples, p < 0.05.
0 was statistically different from 10 TEC, p < 0.05. 20 TEC was statistically different from
both 0 and 10 TEC, p < 0.001. Data are mean ± standard deviation (n=3).
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3.3.4 Mechanical Properties After Incubation
Allowing the films to soak in PBS for 2 hours drastically changed their properties,
with the magnitude of some properties being five times different from those of the dry
samples. With both TEC and TBC films, the UTS, E, and elongation (except for the 20
wt% TEC film) all increased after films soaked in PBS for 2 hours. When comparing the
dry samples to their wet counterparts, the differences were always significant (p <
0.001) for all UTS data for both TEC and TBC samples (Figure 3.7a). The elongation
significantly decreased for 0 and 10 wt% TEC samples when they became wet, but the
20 wt% had an elongation that was the same when wet or dry (Figure 3.7c). For the TEC
samples, the elastic modulus was significantly (p < 0.05) affected by the duration in PBS
for only the 0 wt% films (Figure 3.7b). Elastic moduli for the 0 and 20 wt% TBC films
were significantly (p < 0.05) higher after incubation in PBS. For both TEC and TBC films,
the elongation increased (p < 0.001) for 0 wt% and 10 wt% films, but not 20 wt%.
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(a)

(b)
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(c)

Figure 3.7: A) UTS of dry films and films incubated in PBS for 2 hours. Dry values
compared to degraded values were all significantly different, p < 0.001. B) Elastic
modulus of dry films and films incubated in PBS for 2 hours. 0 films were statistically
different than their degraded counterparts, p < 0.05. 20 TBC was statically different
from its wet counterpart, p < 0.05. C) Elongation of dry films and films incubated in PBS
for 2 hours. Dry 0 and 10 TBC and TEC films were statistically different from their wet
counterparts, p < 0.001. Data are mean ± standard deviation (n=3).

3.3.5 Morphology
Figure 3.8 shows representative SEM images of dry film surfaces and surfaces
and cross‐sectional areas after incubation in PBS for two hours. Samples appeared
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smooth and had no porosity present before incubation. All of the samples had begun
eroding after incubating in PBS for two hours. Porosity was seen both on the surfaces
and in the cross‐sections. As plasticizer content increased, more erosion occurred both
on the exterior and interior of the film, resulting in increased porosity.
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(a)

(b)

(c)

Figure 3.8: Scanning electron micrographs of the as‐prepared surface (top left)
and the surface (top right) and cross‐section (bottom) of films incubated in PBS for 2
hours. A) 0, B) 10, and C) 20 wt% films.
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MicroCT analysis quantitatively confirmed what was seen in the SEM images.
Figure 3.9 shows cross‐sectional slices of representative films before and after two
hours in PBS, and the porosity of each film type is plotted in Figure 3.10. For TEC films,
as plasticizer content increased, so did the porosity. The 20 wt% films increased to 17%
porosity during incubation. The incubated samples were always statistically (p ≤ 0.05)
different from their dry counterparts.

Incubated 0 and 10 wt% samples were

statistically the same, but both were significantly (p < 0.001) different than the porosity
measured in the 20 wt% films. With TBC films, plasticizer content did not affect the
porosity after 2 hours in PBS. Porosity increased uniformly to just under 1%. Pore sizes
for both TEC and TBC films were found to be as small as 6 µm. The majority of the
accessible volume in the films after erosion was from pores with a diameter of less than
20 µm. There were almost no pores present that were larger than 40 µm in either TBC
or TBC plasticized films.

(a)
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(b)

(c)

Figure 3.9: Micro CT images showing A) 0, B) 10, and C) 20 wt% films incubated
in PBS for 2 hours.
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(a)

(b)

Figure 3.10: Porosity measurements for as‐prepared films and films incubated in
PBS for 2 hours. A) TEC‐containing films. 20 TEC was statistically different than 0 TEC, p
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< 0.05. B) TBC‐containing films. No statistical difference between incubated samples,
and no statistical difference between non‐incubated samples.

3.4 Discussion
CAP‐Pluronic films are rigid and unable to conform to the varying topology of
soft tissue defects that may occur in motor vehicle accidents or war wounds. In order to
aid in placement of the films, imparting flexibility and allowing the films to contour to
any shape, plasticizers were added. With the aim of making the FDA approval process
quicker, plasticizers that were already deemed safe were chosen for the CAP‐Pluronic
films.

Both triethyl citrate and tributyl citrate are common plasticizers used in

pharmaceutical and biomedical devices (102, 103, 154, 155).

The United States

Pharmacoepia deems both TEC and TBC appropriate to be used in pharmaceutical
dosage forms (103). They are used in gelatin capsules, enteric coatings on pills, and
transdermal drug delivery patches (154‐156). They are also used in poly(vinyl chloride)
and poly(vinyl acetate) components of medical devices, including tubing and films (157).
Toxicology studies show that take orally, TEC can be toxic to rats at excessively high
doses, corresponding to over half a liter in a 70 kg man. TBC is non‐toxic in rats even at
extremely high doses (158). For a wound that is 10 by 10 centimeters, a layered, drug
loaded film would contain approximately 5 mL of plasticizer (0.07 mL/kg), which is well
within the toxicity limits for a 70 mg man.
Triethyl citrate and tributyl citrate have molecular weights of 276.28 g/mol and
360.45 g/mol, respectively. This means that, for the same weight percent, more TEC
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molecules are present in the films than TBC molecules (TEC: 0.74 mol per film for 10
wt%, TBC 0.58 mol per film for 10 wt%). The same molar concentration was not
compared between TBC and TEC since plasticizers are most commonly added as a
weight percent of the whole polymer. However, the 20 wt% films had 1.57x more
plasticizing molecules than the 10 wt% TEC and they had very similar effects on the %
elongation, UTS, and E, which shows that even with fewer molecules present, TEC
plasticizes to a greater degree than TBC. Plasticizers with a lower molecular weight
cause more flexibility in the material they are incorporated into because they have a
higher mobility and allow polymer chains to more easily slide across one another (156).
With more lubricating plasticizer added to the films, a greater number of molecules
were present between the polymer chains, which thereby increased the molecular
separation and decreased the packing order of CAP and Pluronic F‐127 (103). Because
of this, for the same weight percent of plasticizer added, the TEC had more of an impact
on the mechanical properties of the CAP‐Pluronic F‐127 films.
The mechanical properties changed rapidly after films were incubated in PBS,
because much of the plasticizer leached out in the first two hours of degradation (159).
Mass spectroscopy confirmed the plasticizer leach out by the presence of plasticizer in
the supernatants of plasticized samples (results not shown). The TEC may leach out
more quickly than the TBC because it is more hydrophilic than the TBC, and having
smaller molecules also allowed it to travel down its chemical gradient faster. Triethyl
citrate is a water soluble plasticizer up to 65 g/L, while TBC is a water‐insoluble
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plasticizer (160, 161).

Differences in the solubility of TBC and TEC explain the

differences in the supernatant’s appearance during degradation. The milky appearance
was likely due to the TBC separating out from the PBS solution as the molecules leached
out since it is insoluble in water, while the supernatant from the TEC films remained
clear since it had not reached its solubility limit. Plasticizer leach out will not be an issue
since the polymer will be in the shape of the wound and the film will only become
stronger. After the film has been laid in place, there will no longer be a need for
flexibility and the increased strength of the film will cause it to be a protective barrier
during healing.
Pluronic F‐127 may be eroding at a faster rate than CAP causing the porosity
seen in the 0 wt% films. CAP is commonly used in enteric coatings because of its low
water solubility. It dissolves at higher pH and therefore more slowly than Pluronic F‐127
(162).

This, in addition to the plasticizer leaching out, created the nanometer‐ and

micron‐sized voids seen in the SEM and microCT images. The pores increased the
surface area and allowed the films to degrade at a faster rate. The films containing
more plasticizer may allow the Pluronic degradation to occur more quickly. As voids are
created in the film, PBS can penetrate the films more deeply.

Water causes

disassociation of the hydrogen bonds linking the ether oxygens from the Pluronic F‐127
to the carboxylic acid groups on CAP, leaving behind a material that contains increasing
amounts of CAP relative to all of the other materials. Because CAP is a stronger polymer
than Pluronic and the association polymer they form together, erosion actually
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increased the strength of the material (163, 164). The ultimate tensile strength and
elastic modulus increased since the polymer chains could not stretch and begin to slide
past each other as easily as before incubation. But interestingly, the elongation also
increased. This is likely due to the small holes that were created in the polymer which
allowed it to behave and stretch more like a sponge. As tension was applied to the wet
material, the holes collapsed and caused the remaining chains to elongate. CAP is a
stiffer, slower eroding material than Pluronic F‐127, so even the 0 wt% samples had an
increase in the elastic modulus and ultimate tensile strength as CAP became the
predominant material in the films.
Before plasticization, the CAP‐Pluronic system is less rigid than other drug
delivery polymers such as Eudragit, which has a modulus of 500 MPa or chitosan, which
has a modulus of over 1000 MPa without plasticizer (146, 165). CAP‐Pluronic F‐127 is a
competitive system for drug delivery applications because it is surface eroding so drug is
released as the device erodes, and since it erodes, no material is left behind to cause
inflammation. Another beneficial property is its lower elastic modulus allowing it to be
more flexible and contour and set to the shape of varying wounds when it is plasticized.

3.5 Conclusion
The degradation behavior and mechanical properties of CAP‐Pluronic films can
be varied by the type and amount of plasticizer incorporated into the system. The
material properties will change shortly after the CAP‐Pluronic drug delivery films are
exposed to fluid. These changes do not affect the integrity of the system, since the
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material only gets stronger and will maintain the shape formed in the tissue. The CAP‐
Pluronic system is attractive for a variety of soft tissue drug delivery applications
because it could be tailored to have different properties.
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Chapter 4
The Combined Effects of Drugs and Plasticizers
on the Properties of Drug Delivery Films

This chapter will be submitted for publication, “Rabek C. L., Dziubla T.D., and
Puleo D.A., The Combined Effects of Drugs and Plasticizers on the Properties of Drug
Delivery Films."

4.1 Introduction
Large soft tissue defects are common in motor vehicle accidents as well as in
military injuries. Open wounds accounted for 10.3% of the 5.3 million non‐fatal injuries
from traffic collisions in the U.S. in 2000, and about 50% of all military injuries involve
musculoskeletal wounds to the extremities (1, 2). Aberrant wound healing results in
extended inflammatory phases leading to the formation of fibrotic tissue (7, 12, 166).
The greater the defect size, the longer the healing process will be (167), and infection
and ischemia further prolong inflammation (60, 168). Wound location and the patient’s
health and age also affect duration of the inflammatory phase (169). Secondary union
wounds, where exposed soft tissue requires re‐epithelialization, can result in scar
contractures with negative esthetic and functional consequences (28, 58, 170). As such,
there is a need for treatments that can simultaneously enhance wound healing while
reducing fibrotic scar tissue formation.
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Scar tissue formation could potentially be reduced or prevented if wounds were
treated with individual or a combination of molecules targeted to the specific pathways
of the healing process.

The two drugs used in this study were quercetin and

pirfenidone. Quercetin is a naturally occurring molecule that increases cell proliferation,
decreases superoxide activity, and reduces wound contraction (113, 116, 145, 171).
Reactive oxygen species are predominately released by infiltrating macrophages during
the wound healing process and act as pro‐inflammatory mediators (3). Thus, quercetin
can inhibit oxidative stress to decrease inflammation. Pirfenidone is a pharmaceutical
that has been shown to reduce fibrosis and scarring by down‐regulating adhesion
molecules and certain cytokines and growth factors, including interleukin 1β and
transforming growth factor‐β1 (119‐123).
The wound healing device examined in this study was an erodible drug delivery
film made of cellulose acetate phthalate (CAP) and Pluronic F‐127 (Pluronic) (95). As the
polymer erodes, drugs can be released from the system in a zero‐order manner (96, 99,
151). CAP‐Pluronic films are rigid, glassy polymers, but the addition of plasticizer
increases flexibility, potentially allowing the devices to contour to the shape of varying
wounds (101). The effects of plasticizers, in combination with different drugs, loaded in
CAP‐Pluronic films have not been previously studied. Films containing quercetin or
pirfenidone with either triethyl citrate (TEC) or tributyl citrate (TBC) were investigated to
determine the combined effects of drug and plasticizer on erosion, release, and
mechanical properties.
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4.2 Materials and Methods
4.2.1 Film Fabrication
Cellulose acetate phthalate (Sigma‐Aldrich, St. Louis, MO) and Pluronic F‐127
(Sigma‐Aldrich) were combined in a 70:30 weight ratio, respectively, for a total mass of
2 g per film. Either tributyl citrate (Sigma‐Aldrich) or triethyl citrate (Sigma‐Aldrich) was
combined with the CAP and Pluronic at 0, 10, or 20 wt%. Quercetin (10 or 100 mg;
Sigma‐Aldrich) or pirfenidone (6.1 or 61 mg; Tokyo Chemical Industries, Portland, OR)
was added to the mixture (Figure 1). The low and high loadings of the two drugs are
molar equivalents at 0.033 and 0.33 mol. A 25% (w/v) polymer solution was made by
adding acetone to the CAP, Pluronic F‐127, plasticizer, and drug.

Mixtures were

vortexed to ensure uniform dissolution of the components, cast into Teflon dishes, and
the acetone allowed to evaporate at 10ºC overnight. Films were desiccated overnight
before analysis. Each sample is subsequently referenced by the drug loading within
individual samples (approximately 64 µg, 640 µg, 39 µg, or 390 µg).

a

b

Figure 4.1: Chemical structures of quercetin (a) and pirfenidone (b).
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4.2.2 Erosion and Drug Release Studies
Five millimeter diameter discs were punched from the films. Samples were
weighed to determine their initial mass and placed individually in 24‐well plates. After
adding phosphate‐buffered saline (PBS), pH 7.4, to each well, the plates were gently
agitated on an orbital shaker at 37ºC. Three discs were collected and dried every hour,
and their supernatants were saved for analysis of drug release. PBS in the remaining
wells was replaced with fresh solution every hour. Dried samples were weighed to
determine the final mass for calculating percentage mass loss.
High performance liquid chromatography (HPLC) analysis was performed using a
Shimadzu Prominence system equipped with a Luna C‐18 column (4.6 x 250 mm, 5 µm).
For detection of quercetin, the mobile phase consisted of water containing 0.1%
trifluoroacetic acid and methanol (30:70), with absorbance measurement at 254 nm.
For detection of pirfenidone, the mobile phase consisted of water containing 0.2%
acetic acid and acetonitrile (50:50), with detection at 310 nm. Injection volumes were
50 µl for all samples with a flow rate of 1 ml/min.

4.2.3 Mechanical Properties
Microtensile test samples were punched from the films using a dog bone die
(ASTM D1708) and the width and thickness of each sample measured using digital
calipers. Tensile tests were performed in displacement control mode at a rate of 0.5
mm/sec using a BOSE ELF 3300 system. From the force and displacement data, along
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with the dimensions of each sample, the elastic modulus (E), percent elongation
normalized by the cross‐sectional area, and ultimate tensile strength (UTS) were
calculated.

4.2.4 Statistics
Samples of the same drug molar content, drug type, same plasticizer
concentration, and plasticizer type, were compared against each other. Results were
analyzed using two‐way ANOVA, and a p‐value < 0.05 was considered statistically
significant. Regression comparisons to a 45º line representing surface erosion were
performed on slopes and intercepts of the release vs. erosion plots. A linear regression
p‐value < 0.05 was considered statistically significant.

4.3 Results
4.3.1 Erosion and Release Studies
The mass loss and drug release profiles for 0 and 10 wt% TEC and 0, 10, and 20
wt% TBC films loaded with 64 µg quercetin were linear (Figures 4.2a and 4.3a), with
drug release rates from 9.3 to 13.0%/hr and erosion rates from 7.1 to 9.3%/hr. When
mass loss and release were plotted against each other, quercetin‐loaded TEC and TBC
films followed along or below the 45º line that represents drug release based on only
surface erosion (Figures 4.2b and 4.3b). The mass loss and drug release profiles for 20
wt% TEC films loaded with 64 µg quercetin both appeared more curved than the others
but followed the 45º surface erosion line when plotted against each other. When the
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same molar amount, 0.033 mol per film (39 µg per sample), of pirfenidone was added to
the films, the cumulative drug release profile did not have the same linear behavior
(Figures 4.2c and 4.3c). Over 9% more pirfenidone was released in the first six hours
compared to the quercetin‐loaded films (p < 0.001). None of the TBC‐plasticized,
quercetin‐loaded films reached 80% cumulative release at six hours, but all of the TBC‐
plasticized pirfenidone‐loaded samples had released over 93% of their total loading
(Figures 4.3a, 4.3c, 4.3e, and 4.3g).

Similarly, with the TEC‐plasticized films, the

cumulative release at six hours was under 83% for all of the quercetin‐loaded samples
and was over 92% for all pirfenidone‐loaded samples (Figures 4.2a, 4.2c, 4.2e, and 4.2g).
Pirfenidone release slowed significantly after six hours (Figures 4.2c and 4.3c). The TEC‐
plasticized films loaded with 39 µg pirfenidone released 98% or more of the drug at six
hours, while the 64 µg quercetin‐loaded films had a maximum cumulative release of
91% at that time (p < 0.001). When release from the TEC‐plasticized films loaded with
39 µg pirfenidone was plotted against erosion, the first three data points were not
significantly different from the 45º line for 10 and 20% TEC. For the last five data points,
however, drug release was faster than the rate of mass loss (Figures 4.2d). The erosion
versus release slope in this later region was significantly different from the 45º line (p <
0.01) for both 10 and 20% TEC. The plot of release versus erosion for the TBC‐
plasticized, 39 µg pirfenidone‐loaded films was initially above the 45º line, and even
after the first half of the mass loss, release still increased faster than the films eroded
(Figure 4.3d). When the quercetin loading was increased to 640 µg, TBC films released
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drug over 1.5 times faster than mass was lost and did not fit the erosion‐based model
(Figures 4.3e and 4.3f).

TEC films loaded with quercetin released the drug at a

significantly slower rate than did the TBC films: 52‐56% of the quercetin had been
released by three hours for TEC‐plasticized films, while 74‐80% had been released by
TBC‐plasticized films (p < 0.001). Quercetin release from TEC‐plasticized films better
followed the 45º erosion‐based drug release line (Figures 4.2e and 4.2f). TEC and TBC
films loaded with 39 and 390 µg pirfenidone released drug at a faster rate than erosion
occurred (Figures 4.2f, 4.2h, 4.3f, and 4.3h).
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Figure 4.2: Release and erosion of TEC films loaded with 10 mg quercetin (a), 6.1
mg pirfenidone (c), 100 mg quercetin (e), and 61 mg pirfenidone (g). Release versus
erosion of TEC films loaded with 10 mg quercetin (b), 6.1 mg pirfenidone (d), 100 mg
quercetin (f), 61 mg pirfenidone (h). Data are mean ± standard deviation (n=3).
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Figure 4.3: Release and erosion of TBC films loaded with 10 mg quercetin (a), 6.1
mg pirfenidone (c), 100 mg quercetin (e), and 61 mg pirfenidone (g). Release versus
erosion of TBC films loaded with 10 mg quercetin (b), 6.1 mg pirfenidone (d), 100 mg
quercetin (f), 61 mg pirfenidone (h). Data are mean ± standard deviation (n=3).

4.3.2 Mechanical Properties
Higher plasticizer contents of both TEC and TBC increased the elongation and
decreased the elastic modulus of CAP‐Pluronic films (Figure 4.4). Increased pirfenidone
loading, from 0 to 390 µg, in both TEC and TBC films caused a significant increase in E (p
< 0.001) (Figure 4.4a and Table 4.1). TEC films with 20 wt% plasticizer showed a
significant decrease in E when quercetin loading increased from 0 to 640 µg (p < 0.01)
(Figure 4.4b). The modulus of films plasticized with TBC and loaded with quercetin
increased with drug content from 0 to 64 µg and then decreased from 64 to 640 µg (p <
0.001 for 0 wt%; p < 0.01 for 10 and 20 wt%) (Figure 4.4b). Increasing pirfenidone
loading from 0 to 39 µg significantly decreased elongation for all film types (p < 0.001)
(Figure 4.4c).

Quercetin‐loaded samples had significantly greater elongation with

increasing drug content (p < 0.001) (Figure 4.4d), and they elongated more than did
pirfenidone‐loaded films.

For the same molar drug loading in 20 wt% TEC films,

quercetin samples elongated 17 times more than did those containing pirfenidone (p <
0.001). For 20 wt% TBC, quercetin films elongated 26 times more than pirfenidone‐
loaded samples (p < .001).
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a

b

c

d

Figure 4.4: Elastic modulus of pirfenidone‐loaded films (a) and quercetin‐loaded
films (b). Percent elongation normalized by the cross‐sectional area of pirfenidone
loaded films (c) and quercetin loaded films (d). Data are mean (n=3).
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Table 4.1: Standard deviations of (a) elastic modulus and (b) elongation for
pirfenidone or quercetin loaded films.
a
TEC with pirfenidone

TBC with pirfenidone

TEC with quercetin

TBC with quercetin

Plasticizer

0µg

39µg

390µg

0µg

39µg

390µg

0µg

64µg

640µg

0µg

64µg

640µg

0%

6.21

1.78

69.15

13.00

20.08

69.15

6.21

13.85

6.80

13.00

53.92

20.03

10%

0.43

27.90

44.84

9.84

7.35

56.19

0.43

3.97

3.25

9.84

65.17

7.74

20%

2.89

2.83

9.42

2.44

14.71

33.30

2.89

1.69

0.75

2.44

43.92

7.98

b
TEC with pirfenidone

TBC with pirfenidone

TEC with quercetin

TBC with quercetin

Plasticizer

0µg

39µg

390µg

0µg

39µg

390µg

0µg

64µg

640µg

0µg

64µg

640µg

0%

0.00

0.02

0.01

0.01

0.07

0.01

0.00

0.07

0.017

0.01

0.00

0.16

10%

0.01

0.00

0.02

0.01

0.05

0.01

0.01

0.11

0.28

0.01

0.03

0.30

20%

0.12

0.11

0.03

0.02

0.02

0.01

0.12

0.06

0.38

0.02

0.10

0.50

4.4 Discussion
Two mechanisms govern drug release from CAP‐Pluronic films: erosion and
diffusion (172, 173). Erosion control release occurs when the loaded drug is released at
the same rate at which the polymer vehicle erodes, which in the case of the CAP‐
Pluronic films is a zero‐order process. In diffusion controlled release, water penetrates

57

the material to dissolve the drug or disassociate it from the polymer, thus enabling drug
to diffuse from the matrix. Erosion and diffusion control represent two ends of the
spectrum; release from most degradable or erodible polymer systems fall somewhere
between the two. The mechanism of drug release from unplasticized 70:30 CAP‐
Pluronic films has been shown to be surface erosion (95, 98, 99). Other drug delivery
systems, such as poly(ε‐caprolactone), poly(DL‐lactide‐co‐glycolide), ethylene vinyl
acetate, and starch, are diffusion‐controlled and would leave behind polymer once
release is complete (81, 85, 174‐176). In contrast, CAP‐Pluronic films release drug as
they erode, so material will not remain in the healing wound to cause an inflammatory
reaction after the therapeutic dose is released (10, 97). Polyanhydrides can also be
surface‐eroding systems but require stabilizing co‐monomers increase hydrophobicity to
slow hydrolysis and thereby drug release (177, 178).
The effects of plasticizers on release of drugs from the CAP‐Pluronic system had
not been previously studied. In other polymers, plasticizers can increase or decrease
the rate of release by either increasing the surface area after plasticizer leaches out or
by creating a better barrier to the dissolution media (179, 180). The plasticizers, TEC
and TBC, incorporated into the films are already commonly used in pharmaceuticals and
in biomedical devices (103, 104, 181). Triethyl citrate is a hydrophilic plasticizer with an
aqueous solubility of 12 mg/ml, but TBC exhibits limited solubility at 0.15 mg/ml (182‐
184). Tributyl citrate is a larger molecule than TEC, with molar masses of 276.28 g/mol
and 360.45 g/mol, respectively.
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The two drugs explored, pirfenidone and quercetin, have different solubility in
water, 4.4 and 0.36 mg/ml at 25 ºC, respectively (185, 186). The molar mass of
quercetin is 302.24 g/mol, which is over 1.5 times that of pirfenidone at 185.22 g/mol.
Quercetin also has 12 bonding sites (5 donor and 7 acceptor) that can interact and/or
interfere with the association polymer system. For example, the phenol and enol
groups of the drug can form hydrogen bonds with the ether oxygens in Pluronic F‐127
(186, 187). Additionally, the ketones in quercetin may interact with the carboxylic acid
of CAP. These associations could affect polymer erosion as well as the release of
quercetin from the system. In contrast, pirfenidone has only two acceptor sites on the
amide that could bond with the CAP‐Pluronic system (185). Fewer acceptor sites, a
smaller size, and increased hydrophilicity resulted in pirfenidone being released more
easily from the micron‐sized pores created as the system eroded(101).
Samples containing pirfenidone exhibited a dual mechanism of release. Surface
erosion controlled the first half of the 39 µg pirfenidone release from TEC‐plasticized
films. The first half of release from 39 µg loaded pirfenidone TBC‐plasticized films also
predominantly occurred via surface erosion, but after the fourth hour, release occurred
at a faster rate than polymer mass loss, signifying a transition to diffusion controlled
release. The shift in the main mechanism of release did not occur for the other drug
and plasticizer combinations. The 64 µg quercetin‐loaded films all fit the 45º line
closely, indicating that the mechanism of release was surface erosion. If some diffusion
occurred, the effect was insignificant. Previous work found that film porosity, even in
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unplasticized films, increased significantly after a two hour incubation in PBS (101).
Development of pores increased the surface area by which drug was released from the
surface‐eroding system. As more drug was added to the system, the leading mechanism
of release shifted from erosion to diffusion and increased the release rate. This shift has
been seen in other drug release systems, including atenolol loaded ethylene‐vinyl
acetate films (81). With increased drug loading, the concentration gradient is steeper
and less CAP‐Pluronic is present to control the release. The voids left behind by the
released drug allow molecules deeper in the device to also diffuse out. This was seen
for higher loadings of both quercetin and pirfenidone.
As observed in previous studies, increasing the plasticizer content of both TEC
and TBC led to decreased elastic modulus and increased elongation, resulting in a CAP‐
Pluronic film that will conform better to the complex shapes of wounds (101, 188, 189).
Triethyl citrate plasticized the films to a greater degree than did TBC because it is a
smaller molecule, and for the same mass, there were over 1.25 times as many TEC as
TBC molecules present in the films. Although pirfenidone is a smaller molecule than
either of the two plasticizers, it still may have physically interfered with the ability of
TEC or TBC to plasticize the films by separating the polymer chains and interacting with
the carboxylic acid of CAP. In the unplasticized films, this pirfenidone interaction
reduced what little flexibility the CAP‐Pluronic films alone had, which resulted in an
increased modulus and decreased elongation as pirfenidone content increased. It is not
uncommon to see an “antiplasticizer” effect when small amounts of drug or plasticizer
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are added to polymer (174, 188, 190). The chemical structures of pirfenidone and
quercetin fit Jackson and Caldwell’s “antiplasticizer criteria” because they contain polar
atoms, have at least two nonbridged rings, and have one dimension less than about 5.5
Å (190). The side groups of quercetin likely interacted with both polymers in the CAP‐
Pluronic system to result in synergistic effects on elongation and an increased modulus
(191‐193). The changes in the mechanical properties caused by the plasticizers and
drugs did not correlate with differences in the release profiles. Mechanical testing
occurred when the films were dry, and release occurred when the samples were wet,
however. Previous work found that devices incubated in saline for two hours leached
plasticizer resulting in increased strength (101). This phenomenon has been seen in
other systems before, including sodium alginate‐magnesium aluminum silicate films
plasticized with polyethylene glycol 400 or glycerin (194). The chemical and mechanical
changes that occur once the films are wet reduced any observable difference in the
release.

4.5 Conclusion
Release from drug delivery films, particularly CAP‐Pluronic films, can be
controlled by the amount loaded and the drug properties, including size,
hydrophobicity, and interactive side groups.

The mechanical properties are also

controlled by loading and the drug properties. Plasticizer can be introduced to further
modulate films to achieve the desired mechanical properties. The combined effects of
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drug and plasticizer on the properties of drug delivery films can range from antagonistic
to synergistic. Different drugs and plasticizers can be added to CAP‐Pluronic films to
tailor the erosion, release, and mechanical properties needed for varying applications.
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Chapter 5
Sequential Release of Multiple Drugs from Flexible Drug Delivery Films

This chapter will be submitted for publication, “Rabek C. L., Dziubla T.D., and
Puleo D.A., Sequential Release of Multiple Drugs from Flexible Drug Delivery Films."

5.1 Introduction
Sequential drug release is necessary for targeting the healing phases of soft
tissue defects. After hemostatis, wounds undergo inflammation that, if not controlled,
can result in excessive scar tissue formation during the proliferation stage (28, 195).
Current research in drug delivery devices has fallen short in providing surface eroding
systems capable of delivery multiple drugs in a sequential order and lasting for more
than a couple days (196‐199). In most systems, drug diffuses out leaving behind the
polymer vehicle that could further inflame wounds.
The polymer films explored in this study were composed of cellulose acetate
phthalate (CAP) and Pluronic F‐127 (Pluronic).

Together they form an association

polymer that releases drug as the system erodes. Alone, CAP and Pluronic make a rigid
polymer. To add flexibility to the system and allow it to contour to the shape of varying
wound geometries, plasticizers were added. The two plasticized explored are citrates,
triethyl citrate and tributyl citrate (Figure 5.2).
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Anti-Inflammatory
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Anti-oxidant
Inflammatory cytokine cascade
Fibroblast migration and proliferation
Anti-fibrotic
Myofibroblast differentiation, Matrix deposition
Scar Formation

Figure 5.1: Wound healing stages and the planned drug targets.

The drugs examined during these experiments were chosen to combat the scar
tissue formation outlined in Figure 5.1. The anti‐inflammatory, anti‐oxidant, and anti‐
fibrotic drugs chosen were ketoprofen, quercetin, and pirfenidone, respectively (Figure
5.2). Ketoprofen is an anti‐inflammatory drug that reduces inflammation by non‐
selectively inhibiting cyclooxygenase (COX) (63, 108). Quercetin was the anti‐oxidant
drug chosen because it decreases superoxide activity and reduces wound contraction
(114‐116).

Pirfenidone, an anti‐fibrotic drug, was chosen because it reduced scar

formation by decreasing cell adhesion molecules and reducing cytokines and growth
factors, including interleukin 1β and transforming growth factor‐β1 (119, 121, 123).
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Figure 5.2: Chemical structures of drugs (a) quercetin, (b) ketoprofen, and (c)
pirfenidone, and plasticizers, (d) triethyl citrate and (e) tributyl citrate.

5.2 Materials and Methods
5.2.1 Cytotoxicity Studies
Mouse myoblast cells (C2C12; ATCC CRL‐1772) were seeded into 24‐well plates
at density of 15,000 cells/cm2 and cultured in DMEM supplemented with 10% fetal
bovine serum at 37⁰C in a humidified, 5% CO2 incubator. After 24 hours, the medium
was changed, and cells were exposed to different concentrations of TEC or TBC
plasticizer diluted into the DMEM media for 24 hours. To determine the remaining
viability of the cells after plasticizer exposure, an MTT (3‐(4, 5‐dimethylthiazolyl‐2)‐2,5‐
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diphenyl tetrazolium bromide) assay was performed. Three hundred µLof MTT, 5
mg/mL, were added to each well and incubated for 2 hours. After replacing the medium
with 500 µL of the extraction buffer, 20% sodium dodecyl sulfate in 50% N,N‐dimethyl
formamide, the plates were incubated at 37⁰C on an orbital shaker for 24 hr before
reading absorbance at 570 nm.

5.2.2. Film and Device Fabrication
Polymer films were made by combining Pluronic F‐127 (Sigma‐Aldrich) and
cellulose acetate phthalate (CAP; Sigma‐Aldrich, St. Louis, MO) in a 30:70 weight ratio,
respectively. Triethyl citrate (Sigma‐Aldrich) or tributyl citrate (Sigma‐Aldrich) were
added to the CAP and Pluronic at 0, 10, or 20 wt% to create a 2 g film. Ketoprofen (100
mg; Sigma‐Aldrich), quercetin (10 mg: Sigma‐Aldrich) or pirfenidone (6.13 mg; Tokyo
Chemical Industries, Portland, OR) were combined with the polymers and plasticizer.
Acetone was added to make a 25% (w/v) mixture.

To ensure homogeneity, the

mixtures were vortexed. Then they were poured into Teflon dishes and kept in a 10ºC
refrigerator overnight to let the acetone evaporate slowly.
Two different device types were made, 4‐layered devices and 9‐layered devices.
For the 4 layered devices, films were laminated using acetone and then punched into
cylinders (6 mm). Ketoprofen and pirfenidone loaded films were separated by two
blank films. The cylinders were inserted into polystyrene wells to ensure unidirectional
erosion and release.

Two device orientations were made, “forward” where the
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ketoprofen layer was exposed first and “reverse” where the pirfenidone layer was
exposed first (Figure 5.3).

Figure 5.3: “Forward” (left) and “reverse” (right) device types.

For the 9 layered devices, the films were cut with cylindrical punches of
increasing in diameter (Figure 5.4). The smallest layer (3.8 mm diameter), loaded with
pirfenidone, was covered on either side by a blank layer of a larger diameter (5.5 mm
diameter). The layers were laminated by painting acetone between the films. Larger
diameter quercetin loaded layers (8 mm diameter) encased the blank layers. Another
two blank layers (13.0 mm diameter) covered the quercetin‐loaded layers. Ketoprofen‐
loaded films made up the outermost layers (18.2 mm diameter). All of the devices were
desiccated overnight to remove all remnant acetone. Devices were then desiccated for
24 hours before analysis.
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Figure 5.4: Nine layered device.

5.2.3 Drug Release Studies
Four‐layered devices were placed individually into glass vials with 4 ml of
phosphate‐buffered saline (PBS). Samples were incubated at 37°C on an orbital shaker.
Every 4 hours, supernatants were collected and replaced with fresh PBS. The nine‐
layered devices were placed into 50 mL test tubes with 30 mL of PBS. Every 12 hours,
supernatants were collected (n=3) and replaced with fresh PBS. Supernatants were
analyzed using high performance liquid chromatography (HPLC) to determine drug
release at each time point. HPLC analysis was performed with a Hitachi Primaide system
equipped with a Kinetix C‐18 column (4.6 x 150 mm, 5 µm; Phenomenex). For detection
of ketoprofen, the mobile phase consisted of water containing 0.1% TFA and acetonitrile
(40:60), and UV absorbance was measured at 258 nm. For detection of pirfenidone, the
mobile phase was water containing 0.2% acetic acid and acetonitrile (50:50) and
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measurement occurred at 310 nm. Flow rates were 1 ml/min with injection volumes of
50 µl for all samples.

5.2.4 Erosion Studies
Initial masses were determined for the 9‐layered devices. Every 8 hours devices
were removed from the supernatant, lightly patted dry, and weighed.

5.2.5 Mechanical Properties
A dog bone‐shaped die (ASTM D1708) was used to punch the four‐layered
microtensile test samples. Samples were desiccated overnight before calipers were
used to measure the width and thickness of the laminated samples. Tensile testing was
performed on a BOSE ELF 3300 system in ramp mode with a displacement rate of 0.5
mm/sec. The elastic modulus (E), percent elongation normalized by the cross‐sectional
area, and ultimate tensile strength (UTS) were calculated using the sample dimensions
and force and displacement data.

5.2.6 Statistics
All of the samples of the same plasticizer concentration or plasticizer type were
compared against each other. Results were analyzed using two‐way ANOVA, and a p‐
value < 0.05 was considered statistically significant.
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5.3 Results
5.3.1 Cytotoxicity Studies
Triethyl citrate was significantly less toxic to C2C12 cells than was tributyl citrate
at 0.5, 1, 5, and 10 µL/mL (p < 0.001). Even at low concentrations, 0.5 µL/mL, TBC was
found to be toxic to the cells (Figure 5.5). In contrast, TEC had no significant impact on
cell viability at this concentration. At 10 µL/ml of TEC, only about half of the exposed
cells were still viable. As the concentration of TEC increased, cell viability decreased.
Because of these results, all further studies were performed using only TEC‐plasticized
films.
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Control
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90
80
70
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10

15

20

µL/mL
Figure 5.5: Cell viability after plasticizer exposure. Data are mean ± standard
deviation (n=3).
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5.3.2 Mechanical Properties
Increasing plasticizer concentration increased the elongation and decreased the
ultimate tensile strength and modulus (Figure 5.6).

Layered films that were not

plasticized (0 wt % TEC) had a significantly higher elastic modulus and ultimate tensile
strength than films that were plasticized (p < 0.01 and p < 0.0001, respectively). For
elongation, every increase in plasticizer concentration was significantly different (p <
0.05).
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Figure 5.6: Mechanical properties of 4‐layered devices: (a) % elongation, (b)
ultimate tensile strength, and (c) elastic modulus. Data are mean ± standard error (n=3).
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5.3.3 Four‐Layered Device Release Studies

For the 4‐layered “forward” devices, peaks of ketoprofen and pirfenidone
release occurred at 4 and 16 hours, respectively, regardless of plasticizer concentration
(Figure 5.7). The overlap of the ketoprofen and pirfenidone peaks was 12 hours for all
three plasticizer concentrations. The area under the two release curves corresponds to
overlap release of both ketoprofen and pirfenidone. This “area under the curves” was
also not significantly affected by the plasticizer concentration (Figure 5.8).
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Figure 5.7: Release from “forward” 4‐layered devices plasticized with (a) 0 TEC,
(b) 10 TEC, and (c) 20 TEC. Data are mean ± standard error (n=3).
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Figure 5.8: Area under the curves during ketoprofen and pirfenidone overlap
release from 4‐layered “forward” devices. Data are mean ± standard error (n=3).

For the “reverse” devices, the peak of the first drug, pirfenidone, still occurred at
4 hours (Figure 5.9). The peak of the second drug, ketoprofen, occurred at 24 hours for
0 wt% TEC devices, and at 16 hours for the plasticized devices. The overlap of the
release of both drugs was 12 hours long for the 0 and 10 wt% TEC devices and 16 hours
for the 20 wt% TEC devices.

The area under the curve of the dual release was

significantly different between the 20 wt% TEC devices and the 0 wt% and 10 wt% TEC
devices (p <0.05) (Figure 5.10).
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Figure 5.9: Release from “reverse” 4‐layered devices plasticized with (a) 0 TEC,
(b) 10 TEC, and (c) 20 TEC. Data are mean ± standard error (n=3).
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Figure 5.10: Area under the curves during ketoprofen and pirfenidone overlap
release from 4‐layered “reverse” devices. Data are mean ± standard error (n=3).

5.3.4 Nine‐Layered Device Release Studies

For the 9‐layered devices, overlapping drug release was observed from the first
time point with ketoprofen and quercetin (Figure 5.11). The ketoprofen peak is delayed
with increasing plasticizer; peaks occurred at 8, 24, and 32 hours for 0, 10, and 20 wt%
TEC, respectively. For all three device types, the peak quercetin release occurred at 32
hours.

With increasing plasticizer concentration, the pirfenidone peak is release

occurred earlier. The 0 wt% TEC devices had a pirfenidone peak at 144 hours, the 10
wt% TEC pirfenidone peak occurred at 84 hours, and the 20 wt% TEC devices at 64
hours. Pirfenidone is also more quickly released with increasing plasticizer. Pirfenidone
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is first detected at 96, 64, and 32 hours for 0, 10, and 20 wt% TEC devices, respectively.
Peak pirfenidone release for 0 wt% TEC samples was significantly different from the
peak pirfenidone release from 10 and 20 wt% samples (p < 0.05 and p < 0.001,
respectively).
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Figure 5.11: Instantaneous release from 9‐layered devices plasticized with (a) 0
TEC, (b) 10 TEC, and (c) 20 TEC. Cumulative release from 9‐layered devices plasticized
with (d) 0 TEC, (e) 10 TEC, and (f) 20 TEC. Data are mean ± standard error (n=3).

With increasing plasticizer content, increased mass gain occurred (Figure 5.12).
Eight hours after the study began, the 20 wt% TEC devices gained 1.5 times their initial
mass, the 10 wt% TEC increased in mass by 38%, and the 0 wt% TEC devices gained the
least, with an additional 30% mass.

The mass gain of the 20 wt% samples was

significantly different from the 0 wt% samples (p < 0.01). The slopes of the mass loss
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were 18.8, 21.2, and 25.0 for 0, 10, and 20 wt% TEC devices, respectively. The mass loss
of the 20 wt% samples were significantly different from the 0 and 10 wt% samples (p <
0.001 and p < 0.05, respectively).
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Figure 5.12: Mass loss of 9‐layered devices. Data are mean ± standard error (n=3).

5.4 Discussion
Mouse myoblast cells were analyzed in the cytotoxicity study since they
differentiate into muscle cells; muscle cells are what would be exposed to this polymeric
drug delivery system. Tributyl citrate can be toxic to different organ systems, including
the cardiovascular, respiratory, and central nervous systems (200‐202). However, when
taken orally, it is non‐toxic even in high doses, equating 2 liters in a 70 kg man (158).
Molecules delivered orally must travel from the intestines, through the hepatic portal
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vein, and filter through the liver before circulating through the rest of the bloodstream.
Many TBC molecules are excreted through the process and will never circulate through
the body.

The mouse myoblast cells examined did not have a lymphatic system or

blood vessels to remove the TBC so they were unable to survive the toxic effects.
Compared to mechanical properties of single films plasticized with TEC or TBC
(101), the four‐layered films elongated more and had a lower UTS and modulus. Two of
the four layers were drug loaded. The drug likely acted as plasticizer further affecting
the mechanical properties of the films (191). Because of the additional thickness of the
four‐layered films, it is also possible that the acetone used to laminate the layers was
not able to completely diffuse out of the polymer within 24 hours. Any remnant
acetone would further plasticize the films (203).
Both the “forward” and “reverse” four‐layered devices sequentially released
pirfenidone and ketoprofen. The first drug released always had a sharp peak that
occurred at 4 hours, whereas the second peak was much wider than the first, regardless
of drug order. It was observed during the study that the center of the devices eroded
faster than the outer edges, resulting in donut‐shaped devices in the last few hours of
release. A couple factors likely affected the second peak and the mechanism of erosion;
the geometry and material of the wells. The geometry of the wells allowed for more
turbulence towards the center of the wells; the walls of the wells protected the outer
edges of the films. In addition to the geometry of the wells, the material they were
composed of may also play a role in the inconsistent erosion. Polystyrene is a very
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hydrophobic polymer, it may form nanobubbles on the surface preventing complete
wetting of the material closest to the walls (204). This allowed the last drug‐loaded
layer to erode before the two blank layers separating them had completely eroded
Lastly, CAP‐Pluronic films develop pores as they erode, and these pores could allow for
diffusion of the second drug to extend its release peak (101).
The second drug release profiles in the 0 wt% TEC “forward” and “reverse”
devices were quite different. The “forward” device had a steep slope before and after
the peak release at 16 hours, while, the “reverse” device had a much gentler slope
before and after the peak release. Differences in the drugs account for the release
profiles. Pirfenidone and ketoprofen have different solubilities in water, 4.4 mg/mL and
51 µg/mL, respectively (185, 205). Ketoprofen is also 1.37 times larger than pirfenidone.
Pirfenidone as the second drug was released more easily than ketoprofen. Ketoprofen,
being larger and less water soluble than pirfenidone, cannot as easily diffuse out of the
film as easily as pirfenidone. This is also supported by the differences between the
“forward” and “reverse” overlap release. The “forward” 0 and 10 wt% TEC devices had
larger overlaps of the two drugs than the “reverse” devices. Plasticizer did not affect
release of pirfenidone as the second drug, but it did significantly increase the release of
ketoprofen from 20 wt% TEC “reverse” devices compared to the 0 and 10 wt% TEC
devices.
In the 9‐layered devices, the concentration of TEC affected the release profiles of
the three drugs. Increasing plasticizer increased mobility of the 3 drugs. TEC is 1.5x and
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1.1x larger than pirfenidone and ketoprofen, respectively, and comparable in size to
quercetin. As TEC leaches out of the films, it leaves behind pores large enough for the
drugs to diffuse out (101, 206, 207). This increased porosity also accounts for the mass
gain seen by the 10 and 20 wt% TEC films (208).

5.5 Conclusion
CAP‐Pluronic films are surface eroding systems capable of sequentially releasing
multiple drugs over several days.

The release profiles can be tailored by the

concentration of the plasticizer and by the type of drug loaded into the films. This
makes them to be an appealing system for flexible drug delivery films, particularly for
the prevention of scar tissue formation in soft tissue defects.
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Chapter 6
Comparison of In vitro and In vivo Erosion and Release from Drug Delivery Films

6.1 Introduction
Chronic wound healing occurs when an injury undergoes excessive inflammation
and often results in fibrotic scar tissue that can have both aesthetic and functional
consequences (12, 209). In secondary union wounds, mass amounts of epithelial cells
have been destroyed and the wound cannot be neatly sewn together with sutures. The
healing process is longer and the wound experiences more inflammation than primary
union wounds.

Chronic inflammation causes the differentiation of superfluous

myofibroblasts resulting in the development of fibrotic tissue (210).
Most common treatment for secondary union wounds begins with debridement,
the process of removing foreign debris and dead tissue (6). Macrophages and foreign
body giant cells will work hard to phagocytose debris and necrotic tissue. Once the
wound has been cleaned, bandages will be applied and the wound will be redressed
every couple days (37). During treatment, patients will also be administered oral anti‐
inflammatory drugs to help reduce pain and swelling. Depending on the severity of the
wound, patients may take either non‐steroidal anti‐inflammatory drugs (NSAIDs) or
corticosteroids.

Current treatments do not target the pharmacotherapy for the

different healing stages that occur. Also, with oral medications, much of the dose is lost
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through the first‐pass effect and what makes it to the bloodstream circulates through
the whole body of the patient so most of the remaining molecules are provided to areas
that do not need treatment. Hence, there is a need for localized treatments for soft
tissue defects tailored to the healing process that can prevent or reduce fibrotic scar
tissue formation and encourage proper wound healing.
Films composed of cellulose acetate phthalate (CAP) and Pluronic F‐127
(Pluronic) and plasticized with triethyl citrate (TEC) have been proven to be surface
eroding drug delivery systems capable of sequential release in vitro (95, 97, 99, 211). In
this study, devices made from CAP‐Pluronic films were loaded with anti‐inflammatory,
anti‐oxidant, and anti‐fibrotic dugs to determine the in vivo release profiles. The four
drugs used were meloxicam or ketoprofen, quercetin, and pirfenidone (Figure A.1).
Ketoprofen and meloxicam are common anti‐inflammatory drugs that reduce
inflammation by inhibiting cyclooxygenase (COX); ketoprofen is nonselective while
meloxicam preferentially binds to COX‐2 (63, 108). Quercetin is an anti‐oxidant
biomolecule that has been shown to increase cell proliferation, decrease superoxide
activity, and reduce wound contraction when incorporated into a collagen matrix (114‐
116). Pirfenidone is an anti‐fibrotic drug that has been shown to reduce scar formation
by decreasing cell adhesion molecules and reducing cytokines and growth factors,
including interleukin 1β and transforming growth factor‐β1 (119, 121, 123).
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Figure 6.1: Chemical structures of (a) meloxicam,
(b) ketoprofen, (c) quercetin, and (d) pirfenidone.

6.2. Materials and Methods
6.2.1 CAP‐Pluronic Film Fabrication
Cellulose acetate phthalate (Sigma‐Aldrich, St. Louis, MO) and Pluronic F‐127
(Sigma‐Aldrich) were added in a 70:30 weight ratio to a test tube. Twenty weight
percent triethyl citrate (Sigma‐Aldrich) was combined to the mixture for plasticized
devices. For drug loaded films, pirfenidone, quercetin, ketoprofen, or meloxicam were
added to the 2 g mix of polymers at 6.1 mg, 10 mg, 100 mg, and 45 mg, respectively.
Acetone was added to create a 25% (w/v) solution. To ensure homogeneity, the test
89

tubes were vortexed, then poured into Teflon dishes, and stored at 10ºC overnight.
Acetone evaporation yielded casted films.

Before device fabrication, films were

desiccated overnight.

6.2.2 EVA Film Fabrication
Poly(ethylene‐co‐vinyl acetate) (poly(EVA)) 18 wt% vinyl acetate (Sigma‐Aldrich,
St. Louis, MO) was dissolved in 100 °C toluene to make a 10% w/v solution. Once
homogeneous, the solution was poured into a Teflon dish. Toluene evaporation left
behind a cast film.

6.2.3 Device Fabrication
Cylindrical punches were used to make CAP‐P layers increasing in diameter. The
smallest layer, pirfenidone, was covered by the next smallest and so on until reaching
the outermost drug loaded layer, ketoprofen or meloxicam (Table A.1). Layers were
laminated with acetone. For the devices with backing layers, a poly(EVA) film was used
to ensure unidirectional release. For devices with a mesh encasing, layers were covered
in a polypropylene mesh that was stitched closed with nylon suture (Figure A.2). The
devices were desiccated overnight to remove all remnant acetone.
weighed and measured to determine their initial mass and dimensions.
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Devices were

Table 6.1: Device fabrication information for animal trials
Number of
Study

Backing

Mesh

Drug Loaded

Blank

Plasticizer

Time

Layer

Encasing

Devices

Devices

Types

Points

0% and

48 and

20% TEC

72 hours

Layers
Devices/Rats

Ketoprofen,
9 CAP‐
1

12

Pluronic

No

No

Quercetin,

Yes (6)

Layers
Pirfenidone (6)
Ketoprofen,
5 CAP‐
24 and
2

8

Pluronic

Yes

No

Quercetin,

Yes (4)

20% TEC
48 hours

Layers
Pirfenidone (4)
Ketoprofen,
5 CAP‐
24 and
3

4

Pluronic

Yes

Yes

Quercetin,

No (4)

20% TEC
48 hours

Layers
Pirfenidone (4)
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Table 6.2: Fabrication of devices used for the third trial
Layer

Diameter (mm)

Polypropylene Mesh

19

Poly(EVA)

16.9

Pirfenidone

3.8

Blank

5.5

Quercetin

11

Blank

13

Meloxicam

16.9

Polypropylene Mesh

19

Figure 6.2: Eight layered devices for animal study.
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6.2.4 Animal Methodology and Procedure
The animal study was conducted at the University of Kentucky in accordance
with a protocol approved by the Institutional Animal Care and Use Committee (IACUC).
The study consisted of three separate experiments,: (1) devices without a backing layer
or mesh encasement, (2) devices with a backing layer and no mesh encasement, (3)
devices with both a backing layer and mesh encasement (Table A.2). Twelve week old,
male Sprague‐Dawley rats weighing between 350 and 400 g were used. The surgical
area was prepared by shaving and disinfection with a povidone iodine solution. A
roughly 3 cm incision was made on the left thigh over the quadriceps. Skin was
separated from the muscle to create a pocket for the device. The device was placed
into the pocket with the CAP‐Pluronic side down (Figure 3). The incision was closed
using wound clips. Rats were euthanized after 24, 48, or 72 h, and devices were
retrieved. Final mass and dimensions of the devices were determined.
(a)

(b)

Figure 6.3: Images of animal procedure: (a) implant in surgical site and
(b) wound closure.
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6.3 Results
All devices from the first animal study had completely eroded by the retrieval
time points, 48 and 72 hours. Also, the animal study resulted in unexpected death for
several of the rats implanted with drug loaded devices. The rats had an adverse
reaction to the ketoprofen even though it is an approved and commonly used anti‐
inflammatory drug for rats. Rats that underwent planned euthanasia still had negative
reactions to the ketoprofen, including porphyrin staining and diarrhea, and remained
lethargic 48 hours after implantation.
For the second study, several parameters were modified.

First the anti‐

inflammatory drug choice was changed to meloxicam, another approved anti‐
inflammatory drug for rats. To extend the device length in vivo, polypropylene mesh
backing layers were bonded to the CAP‐Pluronic layers to promote unidirectional
release and erosion. Also, only 20% TEC plasticized devices were used, to reduce the
number of rats needed and evaluate the worst‐case‐scenario in vivo duration devices
(20% TEC devices were the fastest eroding devices).

All of the rats lived until

euthanized. When devices were retrieved at 24 hours after implantation, two of the
four devices had completely eroded leaving behind only a backing layer. By 48 hours, all
four devices had completely eroded.
Further modifications were made to extend the device life in vivo for the third
study. A polypropylene mesh encased the CAP‐P device and backing layer. For this
study, four 20% TEC plasticized, drug loaded devices were used. Table A.3 shows that
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devices used for the 48 hour time points were slightly larger, averaging an additional
0.024 g, or 7.5% more mass, than the devices used for the 24 hour time points. No
blank devices were evaluated in this study. After 24 hours, the two devices lost 91.7% of
their CAP‐Pluronic mass (Figure 4). After 48 hours, the two other devices dropped in
CAP‐Pluronic mass by an additional 2.0%, with a total of 93.7% mass loss.

Table 6.3: Initial and final weights of in vivo device components for third study.
Initial

Initial Weight of

Weight of

Final Weight of

Percentage of

Backing

CAP‐Pluronic

CAP‐Pluronic

Layer (g)

Layers (g)

Remaining

Weight of

Timepoint
Weight

CAP‐Pluronic
Mesh (g)

(hours)
(g)

Layers (g)

24

0.3165

0.2340

0.0700

0.0125

0.0188

8.0342

24

0.3178

0.2446

0.0643

0.0089

0.0208

8.5037

48

0.3259

0.2616

0.0717

0.0126

0.0092

3.8079

48

0.3558

0.2604

0.0737

0.0217

0.0228

8.7558
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Percentage of Remaining CAPP

100.0

100.0

90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0

8.3

10.0

6.3

0.0
0

24

48

Timepoint (hours)
Figure 6.4: Study 3 in vivo CAP‐Pluronic mass loss over time.

6.4 Discussion
Although ketoprofen has been considered a safe anti‐inflammatory drug for use
on rats, this study is not the first to observe adverse reactions. Shientag et al. found
ketoprofen at 5 mg/kg doses to cause gastrointestinal bleeding and ulcers in rats after
24 hours (212). Combining anesthesia with the ketoprofen dose heightened the effects.
Lamon et al. found the toxicity of ketorofen on Sprague‐Dawley rats to be effected by
their genetic strains and certain genotypes exhibited more exaggerated reactions (213).
Ketoprofen is a nonselective cyclooxygenase (COX) inhibitor that interferes with
prostaglandin production and inflammation reducing pain (108). Ketoprofen is known
to irritate the intestine and kidneys resulting in ulcers. Thrombosis, by inhibition of
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thromboxane B2, will allow bleeding to continue from any consequential ulcers (108).
Meloxicam is also an NSAID that is a cyclooygenase inhibitor, preferentially binding to
COX‐2 (108). There is no literature supporting toxic interactions for meloxicam like are
found with ketoprofen; COX‐2 inhibitors are less likely to cause the gastrointestinal and
renal damage that COX‐1 inhibitors do, but they are also less effective as reducing
inflammation (214).
The insignificant difference in erosion after 24 and 48 hours in the third animal
study was caused by geometry changes over time, plasticizer leaching, and also possibly
separation of the poly(EVA) from the CAP‐Pluronic layers that was also seen in the
second study. The ratio of the thickness to the diameter of the devices used in the third
study was about 1:6. The device was thickest in the middle where all 8 layers were and
got increasingly thinner towards the edges where fewer layers made up the thickness.
CAP‐Pluronic films are surface eroding systems (95). The surface area was its largest at
t=0 resulting in the fastest erosion. As the outer edges eroded, the ratio of thickness to
diameter increased and less relative mass was exposed on the surface, which slowed
the erosion rate. The two devices used for the 48 hour time points weighed roughly
7.5% more but were no wider in diameter than the two 24 hour devices. This caused
those two devices to have a lower relative mass exposure from t=0 which in turn
resulted in slower erosion.
Most of the plasticizer leach out occurs in the first few hours of CAP‐Pluronic
erosion (101).

Each CAP‐Pluronic layer contained 20 wt% TEC.
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Because erosion

occurred so quickly, this leaching was captured in the mass loss of the 24 hour time
points but not in the 48 hour time points. Plasticizer leaching has been shown to create
porosity further increasing the surface area and increasing erosion. It is also possible
that the poly(EVA) backing layer separated around the edges from the CAP‐Pluronic
layers allowing erosion to occur from both sides of the CAP‐Pluronic films.
Compared to in vitro studies of layered devices, in Chapter 5, erosion occurred
much faster in vivo. About 94% of the CAP‐Pluronic in the in vivo devices was gone after
48 hours, whereas layered CAP‐Pluronic devices without a backing layer and in sink
conditions only lost 31% after 48 hours. This indicates that there are other factors
increasing the erosion in vivo.
In vitro results cannot always predict what in vivo results will be (215). Chemical,
enzymatic, and mechanical interactions can cause significant differences. Influx of
inflammatory cells, including neutrophils and macrophages, to the wound may have
sped up erosion through phagocytosis of the implant (9, 10, 216). Phagocytosis can
occur for molecules on the micron scale; all of the components of this system, including
the largest two, CAP and Pluronic, are that size or smaller (41, 42, 217). Enzymes in vivo
may also have affected the erosion of the implant. The degree of substitution of
cellulose acetate phthalate is 2.2 which prevents its cellulose backbone from being
broken down into glucose units (218, 219). However, the ester bonds of the phthalic
acid groups could be enzymatically broken.

Since those functional groups are

responsible for the association of the CAP and Pluronic, breaking its ester bond will
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speed up erosion.

In addition, mechanical erosion had a significant impact on the

difference between the in vitro and in vivo results (220). CAP‐Pluronic devices have
been implanted on the calvaria of rats for other studies and significant mass loss after
two days was not observed (97). The location of the implant had a significant effect on
the erosion. The mechanical forces experienced by an implant are very difficult to
model realistically in vitro.

The rats in this study remained active and were not

immobilized in any way. The rats activated their quadriceps anytime they needed to
eat, drink, or play with their cage mate. The device was taut between the skin and
muscle of the rat so as the muscle engaged, the devices were mechanically worn away.
These mechanical forces could not be mimicked in vitro.

6.5 Conclusion
In vivo variances that cannot be replicated in vitro caused the CAP‐Pluronic
devices to erode faster than previously seen. Regardless, CAP‐Pluronic devices still
sequentially release drug and can be loaded with a multitude of molecules to locally
treat an array of conditions. Furthermore, modifications could be made to prolong the
duration of devices if needed, including adding slower degrading polymers between the
layers, and allow for improved control over the drug delivery films.

Copyright © Cheryl Lynn Rabek 2015
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Chapter 7
Conclusion

Improved treatments are needed for soft tissue defects to encourage proper
wound healing and reduce scar tissue formation. In this research, a flexible, layered
drug delivery film capable of sequential, localized release of anti‐inflammatory, anti‐
oxidant, and anti‐fibrotic molecules was developed and characterized to determine if it
was feasible of meeting these needs. In the initial studies, mechanical analysis on
plasticized films demonstrated that the properties and erosion of CAP‐Pluronic films are
varied by the type and amount of plasticizer incorporated into the system.

The

mechanical properties change shortly after exposure to fluid as plasticizer leaches out
leaving behind a stronger film shaped by the surrounding tissue.
The following studies examined how characteristics of drugs, including size,
hydrophobicity, and interactive side groups, influenced the release from CAP‐Pluronic
films. Mechanical properties of the films were also controlled by loading and the drug
properties. Plasticizer can be introduced to further modulate films to achieve the
desired mechanical properties. When drug and plasticizer were combined, the effect on
the film’s properties ranged from antagonistic to synergistic. These studies concluded
that different drugs and plasticizers can tailor the erosion, release, and mechanical
properties needed to target healing in the soft tissue defects.
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Layered CAP‐Pluronic devices proved to be surface eroding systems capable of
sequentially releasing anti‐inflammatory, anti‐oxidant, and anti‐fibrotic molecules over
several days. The devices maintained sequential release regardless of drug order.
Lastly, in vivo variances caused the CAP‐Pluronic devices to erode faster than
previously seen in vitro. Future work would involve reducing the erosion or mechanical
wear. Changing the ratios of CAP to Pluronic, incorporation of a slower eroding polymer
into the films, or modification of the implant site or animal model could also be
explored to extend the device duration in vivo.
Current treatments for soft tissue defects are inadequate because they are
either invasive, require multiple doses, or are not controlled to the healing phases to
obtain optimal healing. CAP‐Pluronic are a promising solution for the prevention of scar
tissue formation in soft tissue defects because they can provide sequential release of
anti‐inflammatory, anti‐oxidant, and anti‐fibrotic drugs locally to healing wounds, which
was the objective of this research.

Copyright © Cheryl Lynn Rabek 2015
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